Phase II study of anhydro-ara-5-fluorocytidine in adenocarcinoma of gastrointestinal tract, epidermoid carcinoma of lung, head and neck, breast carcinoma and small cell anaplastic carcinoma of lung. A study report of the E.O.R.T.C. early clinical trial cooperative group.
D003504:Ancitabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D003561:Cytarabine / Q000031:analogs & derivatives*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*
D003561:Cytarabine; D003504:Ancitabine